GlobalBlock Announces $300,000 Closing of Non-Brokered Private Placement
Calgary, Alberta–(Newsfile Corp. – June 16, 2023) – GlobalBlock Digital Asset Trading Limited (TSXV: BLOK)…
News
EnerSys Hosts 2023 Investor Day
Introduces 2027 Financial Targets and Outlines Strategic Priorities READING, Pa.–(BUSINESS WIRE)–#investorday—EnerSys (NYSE: ENS), the global…
Playbux and iQIYI Globally Launch ‘Watch to Win’
SINGAPORE, Jun 16, 2023 – (ACN Newswire) – Playbux.co, the largest “X” to win web3…
Insurtech Start-Up Breach Launches Carrier, Raises Investment Round Led by RW3 and LightShed Ventures
BOSTON, Jun 16, 2023 – (ACN Newswire) – Breach, an insurtech start-up that is building…
TheMathCompany Recognized Among the Inspiring Workplaces in North America
CHICAGO–(BUSINESS WIRE)–#AI—TheMathCompany, Illinois-headquartered leading global data analytics and engineering firm, earned recognition among the prestigious…
KB Home Announces the Grand Opening of Its Newest Community in Queen Creek, Arizona
The Enclaves at Sonrisa offers personalized, new homes in the Phoenix area close to desirable schools…
ISEE Wins “Autonomous Truck Of The Year” in 2023 SupplyTech Breakthrough Awards
Annual Awards Program Recognizes Innovation in the Global Supply Chain Technology and Logistics Industry CAMBRIDGE,…
Benson Hill Appoints Richard Mack to Board of Directors
Agriculture Industry Executive Brings Nearly Three Decades of Experience to Benson Hill Board ST. LOUIS–(BUSINESS…
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
The treatment combines Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc’s…
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
The treatment combines Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc’s…
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
The treatment combines SciSparc’s Palmitoylethanolamide (PEA), the active pharmaceutical ingredient of its proprietary CannAmide™, and…
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
The treatment combines SciSparc’s Palmitoylethanolamide (PEA), the active pharmaceutical ingredient of its proprietary CannAmide™, and…
PharmAla Biotech Receives Export Permit to Ship GMP LaNeo MDMA to the University of Sydney
Export of LaNeo MDMA Completes August 2022 Contract Fulfillment VANCOUVER, British Columbia, June 16, 2023…
PharmAla Biotech Receives Export Permit to Ship GMP LaNeo MDMA to the University of Sydney
Export of LaNeo MDMA Completes August 2022 Contract Fulfillment VANCOUVER, British Columbia, June 16, 2023…
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf…
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf…
Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.
PALO ALTO, Calif., June 16, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”),…
Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.
PALO ALTO, Calif., June 16, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”),…
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
MINNEAPOLIS, June 16, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive…
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
MINNEAPOLIS, June 16, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive…